Form 8-K - Current report:
SEC Accession No. 0001725160-25-000119
Filing Date
2025-06-02
Accepted
2025-06-02 06:02:38
Documents
15
Period of Report
2025-05-31
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20250531.htm   iXBRL 8-K 33662
2 EX-99.1 a991tieetal_zn-c3x016cli.htm EX-99.1 25571
7 a991tieetal_zn-c3x016cli001.jpg GRAPHIC 2638632
  Complete submission text file 0001725160-25-000119.txt   3840660

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20250531.xsd EX-101.SCH 2039
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20250531_def.xml EX-101.DEF 4226
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20250531_lab.xml EX-101.LAB 24316
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20250531_pre.xml EX-101.PRE 16232
17 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20250531_htm.xml XML 2958
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 251012990
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)